<DOC>
	<DOC>NCT01888822</DOC>
	<brief_summary>The trial aims to assess the value of two-regimen antibiotic prophylaxis versus placebo in elective laparoscopic cholecystectomy.</brief_summary>
	<brief_title>Antibiotic Prophylaxis in Laparoscopic Cholecystectomy</brief_title>
	<detailed_description>All patients enrolled will be submitted to laparoscopic cholecystectomy. The primary aim of the trial will be to assess the role of prophylactic i.v. infusion of ampicillin-sulbactam, ciprofloxacin, and placebo to reduce the rate of surgical site infection.</detailed_description>
	<mesh_term>Cholelithiasis</mesh_term>
	<mesh_term>Cholecystolithiasis</mesh_term>
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<criteria>elective laparoscopic cholecystectomy; patients suffering from gallbladder stones,chronic cholecystitis, cholesterolosis, or gallbladder polyps. acute cholecystitis; acute cholangitis; acute pancreatitis; pregnant or lactating women; antibiotic allergy; antibiotic therapy within 48 hours to 7 days prior to surgery; clinically active infection at the moment of surgery; evidence of common bile duct stones; contraindications for laparoscopic cholecystectomy; no other additional procedure; indication of obligatory antibiotic prophylaxis because the medical condition was different from biliary disease (immunosuppression, corticoid use, etc). patients unable to give informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Laparoscopic cholecystectomy</keyword>
	<keyword>Prophylactic antibiotics</keyword>
</DOC>